celldex therapeutics

celldex therapeutics

NASDAQ:CLDX
Celldex Therapeutics Inc.

Chart

Detailed Quote

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Featured Articles and Interviews
Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress 

The Conversation (0)